Payment overview · 2025
General Payments
$126.30
7 reported records · 4 companies
Healthcare provider profile · identity verified
Felipe Lugo, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SEBRING, FL · NPI 1942658174
Verified facts
What the public records show
CMS Open Payments records show Felipe Lugo, M.D. received $126.30 in general payments during 2025 across 7 reported records.
Amgen Inc. accounted for 36.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.21 | 36.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.24 | 29.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.95 | 19.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.90 | 15.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $126.30 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.76 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.76 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 758 | 232 |
| Levothyroxine Sodium | Levothyroxine Sodium | 450 | 132 |
| Lisinopril | Lisinopril | 397 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 361 | 117 |
| Metformin Hcl | Metformin Hcl | 331 | 111 |
| Losartan Potassium | Losartan Potassium | 296 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 286 | 93 |
| Omeprazole | Omeprazole | 272 | 88 |
| Gabapentin | Gabapentin | 248 | 87 |
| Furosemide | Furosemide | 227 | 72 |
| Alprazolam | Alprazolam | 218 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 201 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 190 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 183 | 60 |
| Simvastatin | Simvastatin | 173 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 58 |
| Glipizide | Glipizide | 148 | 50 |
| Tramadol Hcl | Tramadol Hcl | 138 | 38 |
| Montelukast Sodium | Montelukast Sodium | 135 | 41 |
| Famotidine | Famotidine | 134 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 131 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 40 |
| Alendronate Sodium | Alendronate Sodium | 126 | 44 |
| Allopurinol | Allopurinol | 117 | 36 |
| Potassium Chloride | Potassium Chloride | 116 | 42 |
| Trazodone Hcl | Trazodone Hcl | 115 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 48 |
| Finasteride | Finasteride | 100 | 30 |
| Eliquis | Apixaban | 91 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 90 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 82 | 46 |
| Glimepiride | Glimepiride | 76 | 23 |
| Carvedilol | Carvedilol | 75 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 73 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 70 | 55 |
| Ezetimibe | Ezetimibe | 69 | 24 |
| Pregabalin | Pregabalin | 68 | 25 |
| Lorazepam | Lorazepam | 65 | 15 |
| Warfarin Sodium | Warfarin Sodium | 64 | 13 |
| Ozempic | Semaglutide | 63 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 30 |
| Sertraline Hcl | Sertraline Hcl | 61 | 22 |
| Azithromycin | Azithromycin | 58 | 49 |
| Atenolol | Atenolol | 57 | 16 |
| Baclofen | Baclofen | 56 | 13 |
| Clonazepam | Clonazepam | 54 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 14 |
| Celecoxib | Celecoxib | 51 | 27 |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 16 |
| Jardiance | Empagliflozin | 48 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 46 | 14 |
| Temazepam | Temazepam | 45 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 14 |
| Prednisone | Prednisone | 44 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 14 |
| Metformin Hcl Er | Metformin Hcl | 41 | 12 |
| Spironolactone | Spironolactone | 40 | 18 |
| Ibuprofen | Ibuprofen | 38 | 16 |
| Synthroid | Levothyroxine Sodium | 38 | 13 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 11 |
| Glipizide Er | Glipizide | 34 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | 12 |
| Fenofibrate | Fenofibrate | 32 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | 14 |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 23 |
| Methylprednisolone | Methylprednisolone | 27 | 25 |
| Nitroglycerin | Nitroglycerin | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Meloxicam | Meloxicam | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 12 |
| Bumetanide | Bumetanide | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Jantoven | Warfarin Sodium | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Verquvo | Vericiguat | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Ramipril | Ramipril | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $126.30 · 7 records | Amgen Inc. | EVENITY, FREESTYLE LIBRE, Korlym, OTEZLA, REPATHA, Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error